As medications become increasingly popular to support weight loss, not all of them are approved by the U.S. Food and Drug ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Participants in a new study who used GLP-1 drugs had a much lower cancer risk than those who had bariatric surgery.

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

A KFF survey from 2024 found people had superior weight loss results on Zepbound compared to Wegovy, ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...